Keywords: genmab, 1st-half, loss, falls, sales, hike, danish
Genmab's 1st-half loss falls 54% on sales hike
Article | 03 September 2007
Danish biotechnology firm Genmab AS says that, for the six months ended June 20, 2007, net losses were 87.0 million Danish kroner ($15.9 million) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
